Physician profile
Edward J Ottenheimer
NPI 1881787547
$5,331.11
in general payments reported to CMS, 2019-2025
45 companies · $503 in 2025
The $503 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $250 · 2021: $871 · 2022: $1,040 · 2023: $1,605 · 2024: $772 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,441 · Education: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,440.68 |
| Education | $439.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $599.35 | 2019-2023 | Kyprolis, Vectibix, Xgeva |
| Janssen Biotech, INC. | $531.94 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $328.85 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $304.15 | 2020-2025 | Opdualag |
| Gilead Sciences, INC. | $296.74 | 2021-2025 | Trodelvy |
| Horizon Therapeutics Plc | $293.99 | 2021-2023 | Krystexxa |
| Celgene Corporation | $274.87 | 2021-2025 | Pomalyst, Reblozyl |
| Genentech USA, INC. | $218.19 | 2019-2025 | Polivy, Ocrevus Zunovo, Ocrevus |
| Glaxosmithkline, LLC. | $206.28 | 2021-2024 | Jemperli, Zejula, Ojjaara |
| Novartis Pharmaceuticals Corporation | $182.43 | 2019-2025 | |
| Incyte Corporation | $177.73 | 2021-2024 | Jakafi |
| Sobi, INC | $160.63 | 2022-2024 | |
| Pfizer INC. | $155.21 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $154.36 | 2022-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $139.40 | 2023-2025 | Libtayo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ottenheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.